Genetic alterations predict chemotherapy response:
This article was originally published in Clinica
Identifying certain genetic alterations in colon tumours could help doctors predict the likelihood of a patient responding to chemotherapy after surgery, according to a 460-patient, US study. Stanley Hamilton of the University of Texas MD Anderson Cancer Center, Houston, and colleagues found that patients with an abnormality in chromosome 18 were less likely to survive five years after chemotherapy than those without the abnormality. Patients with two other markers - microsatellite instability and a genetic mutation in a receptor for transforming growth factor (beta) 1 - had a greater chance of survival, according to the study, which appears in The New England Journal of Medicine (April 19).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.